PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

alirocumab vs rosuvastatin/ezetimibe

Side-by-side comparison of alirocumab and rosuvastatin/ezetimibe Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

Drug Class
alirocumab PCSK9 Inhibitor
rosuvastatin/ezetimibe Statin / Cholesterol Absorption Inhibitor
Type
alirocumab Prescription
rosuvastatin/ezetimibe Prescription
Summary
alirocumab

Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.

rosuvastatin/ezetimibe

Roszet contains rosuvastatin, which is a statin medicine. It helps lower bad cholesterol and reduce the risk of heart problems.

What It Treats
alirocumab

Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.

rosuvastatin/ezetimibe

This medicine can help lower LDL cholesterol (bad cholesterol) if you have high cholesterol. It can also slow down the hardening of your arteries. Roszet can also lower triglycerides if you have high triglycerides.

How It Works
alirocumab

Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.

rosuvastatin/ezetimibe

Rosuvastatin blocks a substance your body needs to make cholesterol. This lowers the amount of cholesterol in your blood. It helps prevent heart attacks and strokes.

Common Side Effects
alirocumab
  • Injection site reactions (redness, itching, swelling, pain)
  • Flu
  • Muscle pain
  • Diarrhea
rosuvastatin/ezetimibe
  • Headache
  • Nausea
  • Muscle pain
  • Weakness
  • Constipation
FAERS Reports
alirocumab
  • Muscle pain 1,655
  • Missed dose 1,364
  • Pain at injection site 1,278
  • Muscle spasms 1,162
  • Joint pain 1,053
rosuvastatin/ezetimibe
  • Tiredness 11,698
  • Feeling sick to your stomach 10,037
  • Medicine not working 9,223
  • Difficulty breathing 9,212
  • Loose stools 9,199
Serious Warnings
alirocumab

Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.

rosuvastatin/ezetimibe

Rosuvastatin can sometimes cause muscle problems, including rhabdomyolysis. This can damage your kidneys. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor may do blood tests to check your liver.

Pregnancy
alirocumab

There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.

rosuvastatin/ezetimibe

Rosuvastatin can harm your unborn baby. Do not take this medicine if you are pregnant. Breastfeeding is also not recommended while taking rosuvastatin.

Also Compare — Nearby Drugs

Compare alirocumab with

How to Read This alirocumab vs rosuvastatin/ezetimibe Comparison

alirocumab is classified in the PCSK9 Inhibitor drug class, while rosuvastatin/ezetimibe sits within the Statin / Cholesterol Absorption Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while rosuvastatin/ezetimibe has 49,369. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between alirocumab and rosuvastatin/ezetimibe — always consult your physician or pharmacist first.

Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.